NFL BIOSCIENCES
8announcements published
since October 2026
since October 2026
8in the last 12 months
over the period
over the period
Announcements visible on the feed
A detailed breakdown by type will follow as soon as the taxonomy allows.
Announcements
8Informations privilégiées / Autres communiquésNFL Biosciences : émission et attribution gratuite de bons de souscription d’actions (« BSA ») à tous les actionnaires de la SociétéInformations privilégiées / Autres communiquésNFL Biosciences annonce le recrutement du premier participant dans son étude de phase 2 TONIC évaluant NFL-102 dans le sevrage tabagique et nicotiniqueInside Information / Other news releasesMontpellier, France, November 19, 2026, at 8:00 a.m. CET – NFL Biosciences (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, announces the launch of a financing transaction through the issue and free…Inside Information / Other news releasesNFL Biosciences announces enrollment of the first participant in its Phase 2 TONIC study evaluating NFL-102 for smoking and nicotine cessationInside Information / Other news releasesMontpellier, France, November 13 at 8:30 a.m. CET – NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for the treatment of tobacco dependence, announces the filing of a new patent application aimed at strengthening patent…Informations privilégiées / Autres communiquésMontpellier, France, le 13 novembre à 08h30 CET – NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des immunothérapies pour le traitement de la dépendance tabagique, annonce le dépôt d’une nouvelle demande de brevet destinée à renforcer la…Inside Information / Other news releasesNFL Biosciences will participate in the BIO-Europe 2026 conference to continue discussions with potential partners regarding NFL-101 and NFL-102Informations privilégiées / Autres communiquésNFL Biosciences participera au salon BIO-Europe 2026 pour poursuivre les discussions avec des partenariats potentiels concernant NFL-101 et NFL-102